Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism thymosin alpha 1 agonists(Thymosin alpha-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 3 | CN | 01 Aug 2013 |
Not Applicable | 27 | Thymosin α1 | (cebsmknnpo) = htwrycjzzq sdunmrwnqs (riewkhxuir, 6.6 - 27.2) | Positive | 31 May 2023 | ||
Not Applicable | - | - | (acmzfbjlwi) = vftnpulzuq zorvmdwxzd (xeuhrbsmwx ) View more | Positive | 31 May 2023 | ||
Thymosin α1+CCRT | (acmzfbjlwi) = zgwxcgqthq zorvmdwxzd (xeuhrbsmwx ) View more | ||||||
Phase 2 | 69 | Thymosin α1 + CCRT | dipzpqtjrd(weeytonycc) = fnfqjdniay bsosdrwqko (mdvdrlcsck ) View more | Positive | 20 Jul 2022 | ||
CCRT alone | ypprughrqx(gsrttjqgws) = mpvdkzmqmd wvqybgrqvm (ukzaxvryhd ) View more |